STOCK TITAN

Viridian Therapeutics, Inc. - VRDN STOCK NEWS

Welcome to our dedicated page for Viridian Therapeutics news (Ticker: VRDN), a resource for investors and traders seeking the latest updates and insights on Viridian Therapeutics stock.

Viridian Therapeutics, Inc. (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients suffering from thyroid eye disease (TED). The company's primary product candidate, VRDN-001, is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) that holds promise for treating TED, a rare and debilitating condition.

Viridian Therapeutics leverages cutting-edge science and a deep understanding of disease biology to advance its therapeutic candidates. Their lead candidate, VRDN-001, is aimed at mitigating the symptoms of TED, which include inflammation, pain, and vision impairment. By targeting IGF-1R, VRDN-001 has the potential to offer a novel treatment option for patients who currently have limited choices.

The company’s commitment to scientific excellence is reflected in its rigorous clinical trials and strategic partnerships. Viridian collaborates with leading academic institutions and industry partners to enhance the development and potential commercialization of its therapies. These collaborations provide valuable resources and expertise, helping to accelerate the progress of their drug candidates.

In terms of financial health, Viridian Therapeutics is well-positioned with sufficient funding to advance its clinical programs. The company continuously explores opportunities to bolster its financial stability through strategic partnerships and potential equity financing. Viridian's prudent financial management ensures that it can sustain its operations and continue its mission to bring transformative therapies to patients in need.

Viridian's focus on thyroid eye disease addresses a significant unmet medical need. The company aims to develop treatments that improve the quality of life for patients suffering from this challenging condition. By pursuing innovative approaches and maintaining a patient-centric mindset, Viridian is making meaningful strides in the field of biopharmaceuticals.

Stay updated with the latest news and developments from Viridian Therapeutics as they progress in their mission to deliver groundbreaking therapies for underserved patient populations.

Rhea-AI Summary

On March 8, 2023, Viridian Therapeutics (NASDAQ: VRDN) announced its financial results for Q4 and the full year 2022, highlighting notable advancements in its thyroid eye disease (TED) program. The company reported a net loss of $45.8 million for Q4 and $100.9 million for the year, primarily due to increased R&D expenses. They initiated the THRIVE Phase 3 trial for their lead product candidate, VRDN-001, with topline results expected in mid-2024. The firm anticipates initial results from a proof-of-concept study for chronic TED in Q2 2023. Viridian's cash reserves total $424.6 million, sufficient to fund operations into late 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.48%
Tags
-
Rhea-AI Summary

Viridian Therapeutics (NASDAQ: VRDN) has announced presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society from March 11-16, 2023, in Orlando, Florida. Key highlights include an oral presentation of ongoing Phase 1/2 trial data for VRDN-001, targeting thyroid eye disease (TED), scheduled for March 14. Additionally, four poster presentations will cover the clinical and mechanistic findings of their TED pipeline, which aims to improve treatment for patients. The company is advancing VRDN-001 through its THRIVE Phase 3 trial and planning further studies on other pipeline candidates like VRDN-002 and VRDN-003.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
none
-
Rhea-AI Summary

Viridian Therapeutics (Nasdaq: VRDN) announced on March 3, 2023, that its Compensation Committee approved the grant of non-qualified stock options for 337,000 shares to three new employees. These grants were made outside of the Amended and Restated 2016 Equity Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4). The exercise price is set at the closing stock price on the grant date, with shares vesting over four years. Viridian is focused on developing treatments for serious and rare diseases, particularly advancing its VRDN-001 candidate for thyroid eye disease through both a Phase 3 trial and a Phase 2 proof-of-concept trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
none
Rhea-AI Summary

Viridian Therapeutics (NASDAQ: VRDN) announced a webcast and conference call on March 8, 2023, at 8:00 a.m. ET to discuss its Q4 and full-year 2022 financial results. The session can be accessed via the company’s website under the ‘Events and Presentations’ section. Viridian focuses on developing best-in-class medicines for serious and rare diseases, with ongoing clinical trials for its lead candidate, VRDN-001, targeting thyroid eye disease (TED). The company is conducting a global Phase 3 trial named ‘THRIVE’ and a Phase 2 trial, broadening its pipeline with additional candidates aimed at improving treatment delivery for TED patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
conferences earnings
-
Rhea-AI Summary

Viridian Therapeutics, Inc. (NASDAQ: VRDN) announced that its senior management will present at Cowen’s 43rd Annual Health Care Conference on March 8, 2023, at 1:30 p.m. ET in Boston, MA. A live webcast of the presentation will be available in the Investors section of Viridian's website. The company specializes in developing innovative medicines for serious and rare diseases, focusing on thyroid eye disease (TED). Currently, Viridian is advancing VRDN-001 through a global Phase 3 trial named ‘THRIVE’ and a Phase 2 proof-of-concept trial. The company aims to offer convenient treatment options for TED patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.24%
Tags
conferences
-
Rhea-AI Summary

Viridian Therapeutics, a biopharmaceutical company focused on serious and rare diseases, will participate in a fireside chat at the SVB Securities Virtual Global Biopharma Conference on February 15, 2023, at 1:00 p.m. ET. The event will be accessible via a live webcast on Viridian's website, and a replay will be available afterward. Viridian is advancing its VRDN-001 candidate in global Phase 3 and Phase 2 trials for thyroid eye disease, aiming to deliver best-in-class therapies. The company also develops other candidates targeting autoimmune and rare diseases. For more information, visit viridiantherapeutics.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
conferences
Rhea-AI Summary

Viridian Therapeutics Appoints New CEO

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company, announced the appointment of Scott Myers as President and CEO, effective February 6, 2023. Myers has over 30 years of experience in the biopharmaceutical sector, succeeding co-founder Jonathan Violin, Ph.D. Under Violin's leadership, the company advanced its first Phase 3 trial in Thyroid Eye Disease (TED). Myers aims to leverage his extensive background to transition Viridian into a fully-integrated biopharmaceutical company, focusing on clinical execution and growth. Additionally, he received an inducement award comprising stock options and restricted stock units.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
management
-
Rhea-AI Summary

Viridian Therapeutics, Inc. (Nasdaq: VRDN) announced on February 2, 2023, that its Compensation Committee approved the grant of non-qualified stock options to purchase 332,000 shares to four new employees. This Inducement Grant, made outside the Amended and Restated 2016 Equity Incentive Plan, was essential for the new hires in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price matches the common stock's closing price on the Grant Date, with shares vesting over four years. The company is focused on creating innovative treatments for serious and rare diseases, particularly advancing candidates for thyroid eye disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
none
-
Rhea-AI Summary

Viridian Therapeutics (VRDN) announced positive topline data from its Phase 1/2 trial of VRDN-001, an anti-IGF-1R antibody for active thyroid eye disease (TED). In the latest cohort, 3 mg/kg showed significant improvements: 67% of patients were proptosis responders, and 56% overall responders. Across all cohorts, 71% were proptosis responders, with a favorable safety profile noted. The data support a planned once-monthly subcutaneous dosing for VRDN-002 and VRDN-003. The company is progressing towards pivotal trials and expects to advance its subcutaneous program as a convenient treatment option.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Viridian Therapeutics (NASDAQ: VRDN) announced that its CEO, Jonathan Violin, Ph.D., will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 2:15 p.m. PST in San Francisco. Alongside the presentation, a live Q&A session will begin at 2:35 p.m. PST. Investors can access the live webcast on the company's website, with a replay available until February 8, 2023. Viridian is focused on developing treatments for serious diseases, including ongoing clinical trials for VRDN-001 targeting thyroid eye disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.43%
Tags
conferences

FAQ

What is the current stock price of Viridian Therapeutics (VRDN)?

The current stock price of Viridian Therapeutics (VRDN) is $20.2 as of November 22, 2024.

What is the market cap of Viridian Therapeutics (VRDN)?

The market cap of Viridian Therapeutics (VRDN) is approximately 1.6B.

What does Viridian Therapeutics, Inc. do?

Viridian Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for thyroid eye disease, with a primary focus on their product candidate VRDN-001.

What is VRDN-001?

VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody being developed by Viridian Therapeutics for the treatment of thyroid eye disease.

What condition does Viridian Therapeutics aim to treat?

Viridian Therapeutics is focused on developing treatments for thyroid eye disease, a rare and debilitating condition.

How does VRDN-001 work?

VRDN-001 targets the insulin-like growth factor-1 receptor (IGF-1R) to potentially reduce inflammation, pain, and vision impairment associated with thyroid eye disease.

Who are Viridian Therapeutics' partners?

Viridian collaborates with leading academic institutions and industry partners to enhance the development and potential commercialization of its therapies.

What is the financial condition of Viridian Therapeutics?

Viridian Therapeutics is well-positioned with sufficient funding to advance its clinical programs and explores opportunities for strategic partnerships and equity financing.

Why is thyroid eye disease a focus for Viridian Therapeutics?

Thyroid eye disease represents a significant unmet medical need with limited treatment options, and Viridian aims to develop therapies that improve the quality of life for these patients.

How can I stay updated on Viridian Therapeutics' progress?

You can stay updated by following the latest news and developments from Viridian Therapeutics as they advance their clinical programs and partnerships.

Where is Viridian Therapeutics listed?

Viridian Therapeutics is listed on the NASDAQ stock exchange under the ticker symbol VRDN.

What makes Viridian Therapeutics' approach unique?

Viridian Therapeutics leverages in-depth disease biology knowledge and cutting-edge science to develop innovative therapies, particularly targeting the IGF-1R pathway for thyroid eye disease.

Viridian Therapeutics, Inc.

Nasdaq:VRDN

VRDN Rankings

VRDN Stock Data

1.59B
76.37M
0.01%
112%
13.12%
Biotechnology
Services-medical Laboratories
Link
United States of America
WALTHAM